These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

734 related items for PubMed ID: 20231686

  • 1. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Fernö M, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.
    J Clin Oncol; 2010 Apr 10; 28(11):1813-20. PubMed ID: 20231686
    [Abstract] [Full Text] [Related]

  • 2. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 3. Clinical validation of a customized multiple signature microarray for breast cancer.
    Tan BK, Tan LK, Yu K, Tan PH, Lee M, Sii LH, Wong CY, Ho GH, Yeo AW, Chow PK, Koong HN, Yong WS, Lim DT, Ooi LL, Soo KC, Tan P.
    Clin Cancer Res; 2008 Jan 15; 14(2):461-9. PubMed ID: 18223220
    [Abstract] [Full Text] [Related]

  • 4. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.
    Zentralbl Gynakol; 2006 Apr 15; 128(2):76-81. PubMed ID: 16673249
    [Abstract] [Full Text] [Related]

  • 5. Is triple negative a prognostic factor in breast cancer?
    Nishimura R, Arima N.
    Breast Cancer; 2008 Apr 15; 15(4):303-8. PubMed ID: 18369692
    [Abstract] [Full Text] [Related]

  • 6. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L.
    Cancer Res; 2010 Nov 01; 70(21):8852-62. PubMed ID: 20959472
    [Abstract] [Full Text] [Related]

  • 7. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 8. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
    Clin Cancer Res; 2007 Apr 15; 13(8):2329-34. PubMed ID: 17438091
    [Abstract] [Full Text] [Related]

  • 9. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR, Lee SF, Ringland C, Morey AL, Hanby AM, Morgan G, Byth K, Mote PA, Provan PJ, Ellis IO, Green AR, Lamoury G, Ravdin P, Clarke CL, Ward RL, Balleine RL, Hawkins NJ.
    Clin Cancer Res; 2008 Oct 15; 14(20):6625-33. PubMed ID: 18927304
    [Abstract] [Full Text] [Related]

  • 10. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM.
    J Clin Oncol; 2006 Jul 01; 24(19):3019-25. PubMed ID: 16754938
    [Abstract] [Full Text] [Related]

  • 11. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.
    Ruckhäberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M.
    Breast Cancer Res Treat; 2008 Nov 01; 112(1):41-52. PubMed ID: 18058224
    [Abstract] [Full Text] [Related]

  • 12. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.
    Hum Pathol; 2008 Feb 01; 39(2):167-74. PubMed ID: 18045647
    [Abstract] [Full Text] [Related]

  • 13. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM, Martín A, García C, Corte MD, Alvarez A, Junquera S, González LO, Bongera M, García-Muñiz JL, Allende MT, Vizoso F.
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec 01; 141(2):147-52. PubMed ID: 18768247
    [Abstract] [Full Text] [Related]

  • 14. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, Fendler W, Kubiak R, Pawlowska Z, Morawiec Z, Szemraj J.
    Neoplasma; 2012 Dec 01; 59(4):424-32. PubMed ID: 22489698
    [Abstract] [Full Text] [Related]

  • 15. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL.
    Cancer; 2003 Apr 15; 97(8):1841-8. PubMed ID: 12673709
    [Abstract] [Full Text] [Related]

  • 16. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L.
    Breast Cancer Res Treat; 2008 Mar 15; 108(2):183-90. PubMed ID: 17468948
    [Abstract] [Full Text] [Related]

  • 17. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.
    Breast Cancer Res Treat; 2008 May 15; 109(2):351-7. PubMed ID: 17636399
    [Abstract] [Full Text] [Related]

  • 18. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.
    Hum Pathol; 2006 Sep 15; 37(9):1217-26. PubMed ID: 16938528
    [Abstract] [Full Text] [Related]

  • 19. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.
    Oncol Rep; 2008 Mar 15; 19(3):651-6. PubMed ID: 18288397
    [Abstract] [Full Text] [Related]

  • 20. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T.
    Breast Cancer; 2010 Apr 15; 17(2):118-24. PubMed ID: 19466512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.